|
|
ANN ARBOR, Mich., Jul 31, 2008 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM) ), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will present at the 2008 BMO Capital Markets Focus on Healthcare Conference. The conference will be held August 5-6th at the Millennium Broadway Hotel in New York City. Aastrom will present on Tuesday, August 5, 2008 at 3:00 p.m. (Eastern Time).
A live audio
Continue reading: Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference
ANN ARBOR, Mich., Jun 18, 2008 – Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that on June 18, 2008 the Company received a notice from The Nasdaq Stock Market (Nasdaq) informing the Company, that pursuant to Nasdaq’s previous deficiency letter of December 20, 2007, Aastrom had not regained compliance with Nasdaq Marketplace Rule 4310(c)(4) related to the minimum closing bid price of the Company’s common shares by June 17, 2008. The notice
Continue reading: Aastrom Biosciences Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
ANN ARBOR, Mich., Jun 17, 2008 – Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced plans to initiate a 40 patient U.S. Phase II clinical trial to study the use of Cardiac Repair Cells (CRCs), a mixture of stem and progenitor cells derived from a patient’s own bone marrow, for the treatment of dilated cardiomyopathy (DCM), a severe form of chronic heart failure. Aastrom is now authorized under U.S. Food & Drug Administration
Continue reading: Aastrom to Initiate Phase II Clinical Trial Using Cardiac Repair Cells
ANN ARBOR, Mich., May 5, 2008 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that its Board of Directors will withdraw its proposal to shareholders for approval of the grant of discretionary authority to Aastrom’s Board of Directors to amend the Company’s Restated Articles of Incorporation to effect a reverse stock split. A Special Meeting of Shareholders had been convened on April 8, 2008 and adjourned
Continue reading: Aastrom Biosciences Board of Directors Withdraws Reverse Stock Split Proposal
ANN ARBOR, Mich., Apr 17, 2008 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced encouraging data from the first two compassionate use patients treated with the Company’s autologous stem cell therapy for dilated cardiomyopathy (DCM), a type of severe chronic heart failure. Hans Michael Klein, M.D., Professor of Cardiac Surgery at the Dusseldorf University Hospital in Dusseldorf, Germany performed the first human application of Aastrom’s Cardiac
Continue reading: Aastrom Biosciences Announces Stem Cell Results
|
|
Loading ...